|
Delphinus Medical Technologies, Inc., is a Michigan company that has succeeded in building a three-dimensional full-breast ultrasound imaging device that effectively differentiates benign from malignant masses in breast cancer cases using a safe (non-ionizing), comfortable (non-compressing), and reliable (operator independent) patented technology. Utilizing multi-parametric ultrasound and sophisticated computer algorithms, rather than X-rays, SoftVue safely and comfortably screens women for breast cancer, assesses breast cancer risk, diagnoses breast diseases and monitors therapy. News: January 19, 2011 - Michigan Governor Rick Snyder salutes Dr. Littrup and SoftVue/Delphinus team at State of the State address October 29, 2010 - Delphinus receives grant from the IRS under the Qualifying Therapeutic Discover Project Program. September 2010 - Delphinus receives an additional $1.5 million cash investment from the original VC consortium. July 20, 2010 - Delphinus receives $779,118 in tax incentives from the Michigan Economic Growth Authority. 5/25/2010 - Karmanos Cancer Institute's Delphinus receives $8 million in venture capital for product development of breast cancer imaging tool.
"SoftVue is currently under development and has not received clearance from the FDA at this time"
|
|
